Author(s): Pivrinta M, Tapanainen P, Veijola R
Abstract Share this page
Abstract BACKGROUND: Insulin glargine is a long-acting insulin analogue increasingly used instead of neutral protamine Hagedorn (NPH) insulin in young subjects with type 1 diabetes. OBJECTIVE: We evaluated the clinical course of diabetes in children and adolescents who were switched from NPH to insulin glargine. METHODS: Between August 2003 and November 2004, a total of 76 subjects were switched to glargine in our clinic, treating 340 children with type 1 diabetes. All the subjects had been receiving insulin NPH, and their serum C-peptide levels had been non-detectable for at least 1 yr. Data were collected retrospectively, and 12-18 months after the change, experiences with glargine were inquired using a questionnaire. Seven subjects (9.2\%) discontinued glargine before 12 months, and seven refused to participate. RESULTS: Data for 62 subjects were analyzed. At the switch (0 months), their mean age was 12.7 yr (range 5.1-17.5), mean duration of diabetes was 6.7 yr (range 1.8-14.3), and mean hemoglobin A1c was (HbA1c) 9.2\%. Twelve months later (+12 months), the mean HbA1c remained similar (9.2\%), the proportion of long-acting insulin was smaller (47.7 vs. 58.1\%; p < 0.001), and the daily insulin dose was lower (0.97 vs. 1.05 IU/kg; p < 0.001). The number of injections was lower at +12 months (17.7\% with more than five injections vs. 64.5\%; p < 0.001). No differences were seen in weight for height or the number of severe hypoglycemias. Most subjects who continued with glargine for > or =12 months considered glargine better than NPH. CONCLUSIONS: A switch to insulin glargine retains a similar glycemic control and does not change the number of severe hypoglycemias.
This article was published in Pediatr Diabetes
and referenced in Journal of Diabetes & Metabolism